We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: BRCA2
MedXY News
EnglishTag

BRCA2

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Global Variations in Concurrent Hysterectomy During Risk-Reducing Surgery for BRCA1/2 Carriers: An Integrated Quantitative and Qualitative Analysis
newsBRCA2risk-reducing surgery

Global Variations in Concurrent Hysterectomy During Risk-Reducing Surgery for BRCA1/2 Carriers: An Integrated Quantitative and Qualitative Analysis

By MedXY|Aug 18, 2026

This study reveals significant international differences in concurrent hysterectomy rates during risk-reducing salpingo-oophorectomy among BRCA1/2 variant carriers and explores underlying factors influencing surgical decisions across region

Peritoneal Cancer Risk After Risk-Reducing Salpingo-Oophorectomy: The Impact of BRCA Mutational Status and STIC Lesions
newsBRCA1
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
BRCA2

Peritoneal Cancer Risk After Risk-Reducing Salpingo-Oophorectomy: The Impact of BRCA Mutational Status and STIC Lesions

By MedXY|Mar 15, 2026

This study of 1,351 high-risk women demonstrates that while risk-reducing salpingo-oophorectomy (RRSO) is effective, the presence of serous tubal intraepithelial carcinoma (STIC) at the time of surgery significantly increases the 5-year ris

FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations
newsBRCA2Niraparib

FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations

By MedXY|Dec 16, 2025

The FDA approved once‑daily niraparib plus abiraterone acetate and prednisone for adults with deleterious or suspected deleterious BRCA2‑mutated metastatic castration‑sensitive prostate cancer (CSPC), based on rPFS and interim overall survi

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities